carfilzomib

Carfilzomib (PR-171) is a proteasome inhibitor that irreversibly binds to the chymotrypsin of the 20S proteasome. Carfilzomib has antitumor activity and may be used to treat multiple myeloma.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

CFLZ-567 is a key intermediate for making carfilzomib.

WRR139, a peptide vinyl sulfone, plays a role in disease processes including inflammation and cancer, and acts as an inhibitor of cytosolic enzyme N-glycanase 1 (NGLY1) and Nrf1. Moreover, WRR139 amplifies the cytotoxic effects of Carfilzomib on cancer cells [1].

HRS-4642 is a selective KRAS(G12D) inhibitor (Kd=0.083 nM) with anticancer activity. It demonstrates significant in vivo efficacy in combination with Carfilzomib, synergistically remodeling the tumor microenvironment into an immune-activating one.